Dataset Information

TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients.

ABSTRACT:

Aim

To evaluate the potential prognostic value of GNAS1 T393C polymorphism in advanced non-small cell lung cancer.

Methods

We extracted genomic DNA from the peripheral blood leucocytes of 94 patients with advanced non-small cell lung cancer. Quantitative real-time polymerase chain reaction was used to determine the allelic discrimination. The correlation between genotype and overall survival was evaluated using the multivariate analysis and Kaplan-Meier approach.

Results

Thirty-eight out of 94 (40%) patients displayed a TT genotype, 29 out of 94 (31%) a CT genotype and 27 out of 94 (29%) a CC genotype. The median survival of TT (25 mo) genotype carriers was longer than CT (12 mo) or CC (8 mo) genotype carriers. The favorable TT genotype predicted better overall survival (OS) (2-year OS: 48%; P =0.01) compared with CT (2-year OS: 18%) or CC (2-year OS: 15%) genotype. However, dichotomization between C-genotypes (CC + CT) and T-genotypes (TT) revealed signiﬁcantly lower survival rates (2-year OS: 16%; P = 0.01) for C allele carriers.

Conclusion

Our data provided strong evidence that the GNAS1 T393C genetic polymorphism inﬂuenced the prognosis in advanced non-small lung cancer with a worse outcome for C allele carriers.

SUBMITTER: Gong HY

PROVIDER: S-EPMC4266817 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients.

Gong Hong-Yun HY Hu Wei-Guo WG Wang Xiu-Ling XL Zhu Fan F Song Qin-Bin QB

World journal of gastrointestinal oncology 20141201 12

<h4>Aim</h4>To evaluate the potential prognostic value of GNAS1 T393C polymorphism in advanced non-small cell lung cancer.<h4>Methods</h4>We extracted genomic DNA from the peripheral blood leucocytes of 94 patients with advanced non-small cell lung cancer. Quantitative real-time polymerase chain reaction was used to determine the allelic discrimination. The correlation between genotype and overall survival was evaluated using the multivariate analysis and Kaplan-Meier approach.<h4>Results</h4>Th ...[more]

PMID: 25516778

Similar Datasets

Project description:BackgroundChromosome 1 open reading frame 63 (C1orf63) is located on the distal short arm of chromosome 1, whose allelic loss has been observed in several human cancers. C1orf63 has been reported to be up-regulated in IL-2-starved T lymphocytes, which suggests it might be involved in cell cycle control, a common mechanism for carcinogenesis. Here we investigated the expression and clinical implication of C1orf63 in breast cancer.MethodsParaffin-embedded specimens, clinicopathological features and follow-up data of the breast cancer patients were collected. Publicly available microarray and RNA-seq datasets used in this study were downloaded from ArrayExpress of EBI and GEO of NCBI. KM plotter tool was also adopted. The expression of C1orf63 and CDK10, one known cell cycle-dependent tumor suppressor in breast cancer, was assessed by immunohistochemistry. Western blotting was performed to detect C1orf63 protein in human breast cancer cell lines, purchased from the Culture Collection of the Chinese Academy of Sciences, Shanghai.ResultsIn a group of 12 human breast tumors and their matched adjacent non-cancerous tissues, C1orf63 expression was observed in 7 of the 12 breast tumors, but not in the 12 adjacent non-cancerous tissues (P < 0.001). Similar results were observed of C1orf63 mRNA expression both in breast cancer and several other cancers, including lung cancer, prostate cancer and hepatocellular carcinoma. In another group of 182 breast cancer patients, C1orf63 expression in tumors was not correlated with any clinicopathological features collected in this study. Survival analyses showed that there was no significant difference of overall survival (OS) rates between the C1orf63 (+) group and the C1orf63 (-) group (P = 0.145). However, the analyses of KM plotter displayed a valid relationship between C1orf63 and RFS (relapse free survival)/OS (P < 0.001; P = 0.007). Notablely, in breast cancers with advanced TNM stages (III ~ IV) among these 182 patients, C1orf63 expression was an independent prognostic factor predicting better clinical outcome (HR: 0.41; 95 % CI: 0.17 ~ 0.97; P = 0.042). Additionally, we found that CDK10 mRNA expression was positively correlated with C1orf63, which was consistent with the relationship of protein expression between C1orf63 and CDK10 (r s = 0.391; P < 0.001).ConclusionsCompared to adjacent non-cancerous tissues, C1orf63 expression was elevated in tumor tissues. However, C1orf63 predicts better prognosis for breast cancers with advanced TNM stage, and the underlying mechanism is unknown. In addition, C1orf63 is correlated with the cell cycle related gene, CDK10.

Dataset Information

TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients.

Aim

Methods

Results

Conclusion

Publications

TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets